Stock market correction sends biopharma back to the start of 2021
Covid-19 vaccine developers stand out as global drug stocks tread water in the first quarter.
Go or no go? A delayed decision on Evrenzo
March will see big US decisions for Evrenzo and ide-cel, while tanezumab goes in front of an advisory committee.
Bluebird split looks premature
Today’s safety scare with Lentiglobin calls into question the logic behind Bluebird’s planned business separation.
Aducanumab tops 2021’s biggest potential launches
Blockbuster sales are predicted for several projects nearing approval, from Biogen, Argenx, Fibrogen and others.
